^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Small Lymphocytic Lymphoma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Gazyva (obinutuzumab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    CLL/SLL with del(17p)/TP53 mutation: First-line therapy...Preferred regimens…Venetoclax + obinutuzumab
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Chronic Lymphocytic Leukemia)
    New
    Title:

    venetoclax (Venclyxto®) is accepted for restricted use within NHSScotland.

    Excerpt:
    Venetoclax (Venclyxto®) is accepted for restricted use within NHSScotland....In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)....for use in (1) patients without del (17p)/TP53 mutation who are not fit to receive FCR (fludarabine, cyclophosphamide and rituximab) chemo-immunotherapy and (2) patients with del (17p)/TP53 mutation.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    Excerpt:
    ...- TP53 mutation status (if completed) must be obtained within 12 months prior to registration...
    Trial ID:
    EVOLVE CLL/SLL